⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
INCY News
Incyte Genomics Inc
Syndromic Multiplex Panels Market Strategies, Trends and Forecast 2025-2029: Cost Efficiency, Diagnostic Accuracy, Single-Visit Testing, and Pandemic-Driven Uptake Support Growth
globenewswire.com
ABT
BDX
BIIB
CHE
CTAS
CUE
DHR
DIA
EXPE
GEHC
GILD
HOLX
ICUI
ILMN
INCY
ISRG
LH
LULU
MRNA
NBIX
NOC
ORCL
PDD
PFE
QGEN
QDEL
REGN
ROKU
SNPS
TMO
TSLA
VRTX
XRAY
Incyte gibt positive CHMP-Stellungnahme zu Zynyz ® (Retifanlimab) für die Erstlinienbehandlung von fortgeschrittenem Plattenepithelkarzinom des Analkanals (Squamous Cell Carcinoma of the Anal Canal, SCAC) bekannt
businesswire.com
INCY
Incyte annuncia il parere favorevole del CHMP per Zynyz ® (retifanlimab) per il trattamento di prima linea del carcinoma anale squamocellulare (SCAC) in fase avanzata
businesswire.com
INCY
Incyte annonce un avis favorable du CHMP concernant Zynyz ® (retifanlimab) pour le traitement de première ligne du carcinome épidermoïde du canal anal (SCAC)
businesswire.com
INCY
Incyte anuncia una opinión positiva de Zynyz ® (retifanlimab) del CMUH para tratamiento de primera línea del carcinoma de células escamosas del canal anal avanzado
businesswire.com
INCY
Incyte kondigt positief CHMP-advies aan voor Zynyz ® (retifanlimab) voor de eerstelijnsbehandeling van gevorderd plaveiselcelcarcinoom van de anus (SCAC)
businesswire.com
INCY
Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)
businesswire.com
INCY
CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China
globenewswire.com
INCY
Atopic Dermatitis Market to Reach USD 12.97 Billion by 2034, Growing at 7.75% CAGR
globenewswire.com
REGN
LLY
AMGN
SNY
ABBV
INCY
GSK
PFG
DERM
Incyte to Report Fourth Quarter and Year-End 2025 Financial Results
businesswire.com
INCY